Letter by Jin-shan and Xue-bin Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)"

被引：0
|
作者：
He Jin-shan [1 ]
Li Xue-bin [1 ]
机构：
[1] Peking Univ, Peoples Hosp, Dept Cardiol, Beijing Key Lab Early Predict & Intervent Acute M, Beijing, Peoples R China
来源：
CIRCULATION | 2018年 / 137卷 / 09期
关键词：
D O I：
10.1161/CIRCULATIONAHA.117.031407
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：988 / 988
页数：1
相关论文
共 50 条
  • [1] Letter by Koh Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)"
    Koh, Kwang Kon
    CIRCULATION, 2018, 137 (09) : 984 - +
  • [2] Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)
    Kosiborod, Mikhail
    Cavender, Matthew A.
    Fu, Alex Z.
    Wilding, John P.
    Khunti, Kamlesh
    Holl, Reinhard W.
    Norhammar, Anna
    Birkeland, Kare I.
    Jorgensen, Marit Eika
    Thuresson, Marcus
    Arya, Niki
    Bodegard, Johan
    Hammar, Niklas
    Fenici, Peter
    CIRCULATION, 2017, 136 (03) : 249 - +
  • [3] Letter by Tampaki et al Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)"
    Tampaki, Ekaterini Christina
    Tampakis, Athanasios
    Pantos, Costas
    CIRCULATION, 2018, 137 (09) : 982 - 983
  • [4] Letter by Taegtmeyer and Karlstaedt Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)"
    Taegtmeyer, Heinrich
    Karlstaedt, Anja
    CIRCULATION, 2018, 137 (09) : 986 - 987
  • [5] Response by Kosiborod et al to Letters Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)"
    Kosiborod, Mikhail
    Cavender, Matthew A.
    Fu, Alex Z.
    Wilding, John P.
    Khunti, Kamlesh
    Holl, Reinhard W.
    Norhammar, Anna
    Birkeland, Kare I.
    Jorgensen, Marit Eika
    Thuresson, Marcus
    Arya, Niki
    Bodegard, Johan
    Hammar, Niklas
    Fenici, Peter
    CIRCULATION, 2018, 137 (09) : 989 - 991
  • [6] Sodium-glucose cotransporter-2 inhibitors and cardiovascular outcomes: insights from the CVD-REAL study
    Saad, Marwan
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
  • [7] Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data
    Khunti, Kamlesh
    Kosiborod, Mikhail
    Kim, Dae Jung
    Kohsaka, Shun
    Lam, Carolyn S. P.
    Goh, Su-Yen
    Chiang, Chern-En
    Shaw, Jonathan E.
    Cavender, Matthew A.
    Tangri, Navdeep
    Franch-Nadal, Josep
    Holl, Reinhard W.
    Jorgensen, Marit E.
    Norhammar, Anna
    Eriksson, Johan G.
    Zaccardi, Francesco
    Karasik, Avraham
    Magliano, Dianna J.
    Thuresson, Marcus
    Chen, Hungta
    Wittbrodt, Eric
    Bodegard, Johan
    Surmont, Filip
    Fenici, Peter
    CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [8] Sodium-glucose cotransporter 2 inhibitors compared with other glucose-lowering drugs in Japan: Subanalyses of the CVD-REAL 2 Study
    Kohsaka, Shun
    Takeda, Masayoshi
    Bodegard, Johan
    Thuresson, Marcus
    Kosiborod, Mikhail
    Yajima, Toshitaka
    Wittbrodt, Eric
    Fenici, Peter
    JOURNAL OF DIABETES INVESTIGATION, 2021, 12 (01) : 67 - 73
  • [9] Comparative effectiveness of cardiovascular outcomes in new users of sodium-glucose cotransporter-2 inhibitors: SGLT2 inhibitors in the real world
    MacIsaac, Richard J.
    Ekinci, Elif I.
    ANNALS OF TRANSLATIONAL MEDICINE, 2017, 5 (23)
  • [10] Sodium-Glucose Cotransporter-2 Inhibitors for Heart Failure: The New Kid on the Block
    McDermott, Jaime
    Tennyson, Carolina
    Bell-McClure, Elizabeth
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2021, 17 (06): : 652 - 656
12345